Vaccines

The biotech's blockbuster Nasdaq debut provides crucial capital for its promising pipeline, offering new hope for patients with severe bleeding conditions.

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Valitor's VLTR-559 shows superior durability in preclinical data, potentially slashing wet AMD treatment from monthly injections to just two per year.

An ultra-rare disease affects thousands, but few are diagnosed. Now, a new alliance of industry and advocates is racing to solve the diagnostic puzzle.

With $2.5M in seed funding, Hamilton's Stoked Bio is using a novel AI platform to tackle the world's toughest diseases, from superbugs to brain cancer.

Biotech firm Ocubio adds commercial titan Jim Mazzo and clinical pioneer Dr. Eric Donnenfeld, signaling a major play to disrupt the ocular health market.

With double-digit growth and key US acquisitions, ESTEVE is rapidly expanding. But it's the firm's B Corp status that may redefine success in pharma.

New Phase III data shows a dual-action drug delivers significant weight loss while targeting liver health, positioning it as a major new player in the market.

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Scottish biotech EnteroBiotix secures major funding to advance its gut therapy for IBS-C, offering new hope for a disease-modifying treatment.

Vensica Medical gets FDA clearance for a Phase 2 study of its ultrasound device that delivers botulinum toxin without needles for overactive bladder.

A new HHS agenda reopens the door for controversial peptides, just as a wave of next-gen obesity drugs threatens to upend the entire market.

Umoja Biopharma's UB-VV500 aims to revolutionize myeloma care by creating a dual-antigen CAR T therapy directly inside the patient's body.

A new study shows treating chronic Lyme disease reversed key Alzheimer's biomarkers, challenging medical guidelines and offering a new path for brain research.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

A landmark study reveals essential phospholipids significantly reduce liver fat and fatigue in MASLD patients, offering a new tool against a silent epidemic.

A novel alpha-radiation therapy, Alpha DaRT, begins European trials, offering a new path for pancreatic cancer patients with no other treatment options.

With its Nasdaq debut, Lakewood-Amedex aims to accelerate its novel antimicrobial, Nu-3, a new weapon against antibiotic-resistant diabetic foot ulcers.